A Study to Assess if Mirikizumab is Effective and Safe Compared to Secukinumab and Placebo in Moderate to Severe Plaque Psoriasis (OASIS-2)

ID#: NCT03535194

Age: 18 years - 66+

Gender: All

Healthy Subjects: No

Study Phase: Phase 3

Recruitment Status: Recruiting

Start Date: June 26, 2018

End Date: April 09, 2020

Contact Information:
There may be multiple sites in this clinical trial. 1-877-CTLILLY
1-317-615-4559
Summary:

The reason for this study is to see how effective and safe mirikizumab is compared to secukinumab and placebo for moderate to severe plaque psoriasis.

Eligibility:



Inclusion Criteria:

- Participant must have chronic plaque psoriasis for at least 6 months.

Exclusion Criteria:

- Participant must not be breastfeeding or nursing woman.

- Participant must not have had serious, opportunistic, or chronic/recurring infection within 3 months.

- Participant must not have received a Bacillus Calmette-Guerin (BCG) vaccination within 12 months or received live vaccine(s) (including attenuated live vaccines) within 12 weeks of baseline or intend to receive either during the study.

- Participant must not have any other skin conditions (excluding psoriasis).

- Participant must not have previous exposure to Cosentyx and any other biologic therapy targeting IL-17 (including Taltz).

- Participant must not have received anti-tumor necrosis factor (TNF) biologics within 8 weeks.

- Participant must not have previous exposure to any biologic therapy targeting IL-23 (including Stelara).

Find a Clinical Trial Find Cancer Clinical Trials